Who is advising Obama during the transition? An army of well connected people. Here are the team leaders for economics and international trade. Many have past public service and current charity work. For those now working in the for-profit sector, we have emphasized only the business ties.
Economics and International Trade Team Leads
Corporate, Investment, Law Firm and Consultant
Today I am at Harvard, attending a workshop titled: Unbranding Medicines: the politics, promise, and challenge of generic drugs. This is put on by the Harvard Interfaculty Initiative on Medicines and Society. The program in general is quite impressive, particularly as regards to the depth of experience and knowledge about the generic drug industry, including its early origins.
I was asked to speak about the use of prizes. The slides from my presentation are here:
6 December 2008
At the close of the final day of the 3rd Internet Governance Forum in Hyderabad, India, the Dynamic Coalition on Open Standards (DCOS) released an agreement entitled the “Dynamic Coalition on Open Standards (DCOS) Agreement on Procurement in Support of Interoperability and Open Standards.”
Under the procurement agreement, governments, publicly funded and non-profit institutions agree to promote interoperability and accessibility through the use of open standards.
This is from an exchange on IP-Health.
———–
Dear Aidan and Thomas.
There are several things I could mention about this revised position on compulsory licenses, but I will begin with these.
Yesterday December 1 2008, professors Aidan Hollis and Thomas Pogge presented their Health Impact Fund (HIF) proposal at Georgetown University in Washington, DC.
The meeting convened and moderated by the President of Georgetown University, Jack deGioia, was attended by 50/60 people and was structured with two presentations by the co-authors and a panel discussion by :
Paul Antony, M.D., Chief Medical Officer and Executive Director, PhRMA
Lawrence Gostin, J.D., Associate Dean and Timothy and Linda O’Neill Professor of Global Health Law, Georgetown University Law Center
Continue Reading
On November 25, 2008, I was invited to give a talk in Vienna, at the meeting of the Chamber of Commerce (the WKO). The event was organized by Eva Lichtenberger, a Green Party MEP. Eva also spoke, and gave a great talk, in German. Her slides were in English, and I’ll add them when I can. The outline of my talk is given below.
On November 25, 2008, I was invited to give a talk in Vienna, at the meeting of the Chamber of Commerce (the WKO). The event was organized by Eva Lichtenberger, a Green Party MEP. Eva also spoke, and gave a great talk, in German. Her slides were in English, and I’ll add them when I can. The outline of my talk is given below.
In an exchange on the i+a listserve, I asked Professor Pogge if the decision to reject open licensing was in part because he was concerned about opposition from certain elements of the pharmaceutical industry. This was his response, shared here with permission:
In their recent book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss a number of issues. This is what they say about compulsory licensing of patents.
Page 53-54
In their recent book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss a number of issues. This is what they say about S.2210 (110th Congress), Senator Sanders’ proposal for the Medical Innovation Prize Fund.
Page 105-106
Medical Innovation Prize Act of 2007